Catalogo dei Corsi di studio

CURRICULUM VITAE DANILO TONI, MD, PhD

1984 MD
1985-1986 Medical Officer at the Neuropsychiatric Department of the military hospital of Rome
1984-1988 Resident in Neurology Department of Neurological Sciences, University La Sapienza
1989-1992 PhD in Neuropathophysiology and Neurorehabilitation, University "La Sapienza"
Current position Professor of Neurology Department of Human Neurosicenceces; Director Emergency Department Stroke Unit of the Dept. of Human Neurosciences, University La Sapienza

Memberships Past President of the Italian Stroke Organisation
European Stroke Organisation: member of the following Committees:
- Stroke Guidelines Committee (until 2018)
- Board of Directors (until 2014)
- Stroke Unit certification Committee (until 2014)
- Stroke Trial Outcome Measures harmonization Committee (until 2014)
- Stroke Trial Network Committee (until 2014)
Italian Society of Neurology
European Academy of Neurology
World Stroke Organisation
Association of Emergency/urgency Neurology
ISO-SPREAD Italian guidelines

Publications he has extensively published in the research field of acute stroke more than 400 original articles, abstracts, congress presentations, books chapters and one book
Main journals of publications: N Engl J Med, J Am Med Ass, Lancet, Lancet Neurol, Brit Med J, Stroke, Neurology, Arch Neurol, J Neurol Neurosurg Psych, Cerebrovasc Dis, Int J Stroke
H-Index: 63 (Scopus); 76 (Google scholar)
Total N Quotations: 42.707
Research activities:
- Search of clinical/instrumental data (neuroimages and/or ultrasounds of extra- and intracerebral arteries) detected in the very early hours after symptom onset Fundamental information to plan therapies for both the acute phase and the subsequent rehabilitation
- Early diagnosis of ischemic stroke subtypes through the comparison between clinical syndromes, lesions detected by neuroimages (CT or MR) and possible embolic sources evidenced by ultrasound studies of cerebral arteries and heart. Classification with prognostic and therapeutic implications.
- Search of pharmaceutical treatments able to limit brain tissue damage and to improve the clinical outcome of ischemic stroke patients. Translational clinical research on drugs shown to be effective in animal models of ischemic stroke.
- Clinical trials tested various neuroprotectant agents and drugs able to reperfuse the ischemic brain, with two fundamental discoveries:
the efficacy of recombinant tissue-type Plasminogen Activator in real world (SITS-ISTR registry)
the efficacy of recombinant tissue-type Plasminogen Activator when administered within 4.5 hours of stroke onset. (ECASS IV trial) and between 4.5 and 9 hours in patients selected with DW/PW MR (ECASS IV trial)
- Search of treatments able to limit brain tissue damage and to improve clinical outcome of patients with brain hemorrhage. In particular, recombinant activated factor VII and an aggressive antyhypertensive regimen were tested

Editorial activities::
European Stroke Journal (Editorial Board)
Stroke
New England Journal of Medicine
Britsh Medical Journal
Lancet Neurology
Circulation
Neurology
Cerebrovascular Diseases
International Journal of Stroke
Journal of Neurology
Journal of Neurointerventional Surgery
Neurological Sciences
PLOSone
European Neurology
European Journal of Neurology
CNS Drugs
Journal of Brain Research
Journal of Neuropsichiatry and Clinical Neurosciences
Hypertension
Internal and Emergency Medicine
Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Disease Markers

Experiences in therapeutic trials
1985-1987 Italian Acute Stroke Study Hemodilution + Drug (IASSH + D): randomized controlled trial combining hemodilution with the neuroprotectant ganglioside GM1 in ischemic stroke
1987-1989 Early Stroke Trial (EST): randomized controlled trial with the neuroprotectant ganglioside GM1 in ischemic stroke
1990-1991 Asclepios Study-Isradipine: randomized controlled trial with the neuroprotectant calcium-antagonist isradipine in ischemic stroke
1993 -1995 ECASS I*: randomized controlled trial of reperfusion with recombinant tissue type Plasminogen Activator (rt-PA)within 6 hours after onset of an ischemic stroke
1994-1997 TESS (Tirilazad European Stroke Study): randomized controlled study of tirilazad (neuroprotectant) in acute ischemic stroke
1995-1996 EPSS (Early Progressing Stroke Study): observational study on mechanisms of early impairment of patients with ischemic stroke
1997-1998 ECASS II*: randomized controlled trial of reperfusion with rt-PA within 6 hours after onset of an ischemic stroke
2000-2001 mRECT: Repinotan in acute stroke: randomized controlled trial with the neuroprotectant antioxidant repinotan in ischemic stroke
2000-2004 RAPID (Rapid Anticoagulation Preventing Ischemic Damage)*: randomized controlled trial with i.v. heparin in ischemic stroke
2002-2003 STACI: Surgical Treatment of Acute Cerebral Ischemia: italian registry of emergent/urgent carotid endarterectomy in ischemic stroke
2003-2006 SITS-MOST (Safe Implementation of Thrombolysis in Stroke Monitoring Study)*;**International registry on i.v. thrombolysis with rt-PA in ischemic stroke
2003-2007 ECASS III*: randomized controlled trial of reperfusion with rt-PA given 3 to 4.5 hours after onset of an ischemic stroke
2003-2007 PRoFESS***: randomized controlled trial of secondary prevention in ischemic stroke with aspirin+dipiridamole compared to clopidogrel, and with telmisartan compared to placebo
2005-2007 FAST: randomized controlled trial with recombinant factor VII in intracerebral hemorrhage
2007-2012 TESPI****: Thrombolysis in elderly Stroke Patients in Italy: randomized controlled trial with i.v.t-PA vs standard treatment within 3 hrs of stroke in patients aged over 80 year (proponent of the study protocol)
2009-2011 DIAS 4*****: randomized controlled trial with i.v. desmoteplase within 3 to 9 hours after onset of an ischemic stroke
2008-2015 IRIS: randomized controlled trial of secondary prevention in patients with insulin resistance treated with pioglitazone
2010-2012 INTERACT2: randomized controlled trial with aggressive versus guideline blood pressure treatment in intracerebral hemorrhage
2010- STACI 2***: randomized controlled trial of early versus delayed carotid
endarterectomy in patients with ischemic stroke (in corso)
2012-2017 ECASS IV***: randomized controlled trial with i.v. t-PA between 4.5 and 9 hours of ischemic stroke onset
2015-2018 NAVIGATE-ESUS*;***: randomized controlled trial comparing rivaroxaban to aspirin in patients with embolic stroke of undetermined source (ESUS)
2015-2018 RE-SPECT-ESUS*;***: randomized controlled trial comparing dabigatran to aspirin in patients with embolic stroke of undetermined source (ESUS)
2015- SAFFO****: Silent Atrial Fibrillation aFter stroke, randomized controlled trial searching atrial fibrillation with implantable loop recorder or standard follow-up in patients with atherothrombotic or lacunar infarct (ongoing) (proponent of the study protocol)
2015- OPTION**: national register of patients with cryptogenic ischemic stroke and patent foramen ovale submitted or not submitted to percutaneous closure (ongoing) (proponent of the study protocol)
2015- ASTER****: national register of Prospective Risk of ICH after Acute Stroke Under Oral Anticoagulants (ongoing) (proponent of the study protocol)
2018-2019 RESTORE-BRAIN*: randomized controlled trial comparing GABA-A subunit antagonist to placebo to test functional recovery from ischemic stroke
2018-2020 THALES*: randomized controlled trial comparing ticagrelor+ASA vs ASA in early secondary prevention of ischemic stroke
2019- CHARM*: randomized controlled trial comparing glibenclamide to standard treatment in patients with malignant infarction
2019- ANNEXXA-I *: randomized controlled trial comparing andexanet to standard treatment in patients with brain hemorrhage while on therapy with anti-Xa drugs
2019- AXIOMATIC-I*: randomized controlled trial comparing dual antiplatelet therapy (ASA+clopidogrel) plus anti-IXa compound to dual antiplatelet therapy (ASA+clopidogrel)

* National Coordinator; ** Member of the Executive Committee; *** Member of the Steering Committee;**** Chairman; *****Member of the International Advisory Board

International Awards
1994 Young investigator award during the 3rd European Stroke Conference , Stockholm 1994.
1995 Prize for excellence in stroke research during the 4th European Stroke Conference , Bordeaux 1995
1996 Nomination to the First Sanofi prize for stroke research Cerebral embolism during the 3rd World Stroke Congress and 5th European Stroke Conference
2021 The Spirit of Excellence Award for Commitment to excellence in stroke care. ESO/Angels

CURRICULUM VITAE DANILO TONI, MD, PhD

1984 Laurea Medicina e Chirurgia
1985-1986 Ufficiale Medico Reparto Neuropsichiatria Ospedale Militare Celio di Roma
1984-1988 Specializzazione Neurologia Università La Sapienza
1989-1992 Dottorato Neurofisiopatologia e Neuroriabilitazione Università La Sapienza

Posizione attuale: Professore Ordinario Dipartimento di Neuroscienze Umane
Direttore Unità di Trattamento Neurovascolare, Dipartimento di Emergenza
Policlinico Umberto I Sapienza Università di Roma

Società Scientifiche: Past Presidentt Italian Stroke Organisation
European Stroke Organisation: membro dei seguenti Committees:
- Stroke Guidelines Committee (until 2018)
- Board of Directors (until 2014)
- Stroke Unit certification Committee (until 2014)
- Stroke Trial Outcome Measures harmonization Committee (until 2014)
- Stroke Trial Network Committee (until 2014)
- Socientà Italiana di Neurologia
- World Stroke Organisation
- European Academy of Neurology
Associazione Neurologia d Urgenza
- Linee guida ISA-SPREAD

Pubblicazioni più di 400 articoli originali, abstract, presentazioni a congresso, capitoli di libri
Principali riviste sicentifiche:: N Engl J Med, J Am Med Ass, Lancet, Lancet Neurol, Brit Med J, Stroke, Neurology, Arch Neurol, J Neurol Neurosurg Psych, Cerebrovasc Dis, Int J Stroke
H-Index: 63 (Scopus); 76 (Google scholar)
N° Totale citazioni: 42.707
Attività editoriali::
European Stroke Journal (Editorial Board)
Stroke
New England Journal of Medicine
Britsh Medical Journal
Lancet Neurology
Circulation
Neurology
Cerebrovascular Diseases
International Journal of Stroke
Journal of Neurology
Journal of Neurointerventional Surgery
Neurological Sciences
PLOSone
European Neurology
European Journal of Neurology
CNS Drugs
Journal of Brain Research
Journal of Neuropsichiatry and Clinical Neurosciences
Hypertension
Internal and Emergency Medicine
Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Disease Markers

Esperienze trial clinici
1985-1987 Italian Acute Stroke Study Hemodilution + Drug (IASSH + D): randomized controlled trial combining hemodilution with the neuroprotectant ganglioside GM1 in ischemic stroke
1987-1989 Early Stroke Trial (EST): randomized controlled trial with the neuroprotectant ganglioside GM1 in ischemic stroke
1990-1991 Asclepios Study-Isradipine: randomized controlled trial with the neuroprotectant calcium-antagonist isradipine in ischemic stroke
1993 -1995 ECASS I*: randomized controlled trial of reperfusion with recombinant tissue type Plasminogen Activator (rt-PA)within 6 hours after onset of an ischemic stroke
1994-1997 TESS (Tirilazad European Stroke Study): randomized controlled study of tirilazad (neuroprotectant) in acute ischemic stroke
1995-1996 EPSS (Early Progressing Stroke Study): observational study on mechanisms of early impairment of patients with ischemic stroke
1997-1998 ECASS II*: randomized controlled trial of reperfusion with rt-PA within 6 hours after onset of an ischemic stroke
2000-2001 mRECT: Repinotan in acute stroke: randomized controlled trial with the neuroprotectant antioxidant repinotan in ischemic stroke
2000-2004 RAPID (Rapid Anticoagulation Preventing Ischemic Damage)*: randomized controlled trial with i.v. heparin in ischemic stroke
2002-2003 STACI: Surgical Treatment of Acute Cerebral Ischemia: italian registry of emergent/urgent carotid endarterectomy in ischemic stroke
2003-2006 SITS-MOST (Safe Implementation of Thrombolysis in Stroke Monitoring Study)*;**International registry on i.v. thrombolysis with rt-PA in ischemic stroke
2003-2007 ECASS III*: randomized controlled trial of reperfusion with rt-PA given 3 to 4.5 hours after onset of an ischemic stroke
2003-2007 PRoFESS***: randomized controlled trial of secondary prevention in ischemic stroke with aspirin+dipiridamole compared to clopidogrel, and with telmisartan compared to placebo
2005-2007 FAST: randomized controlled trial with recombinant factor VII in intracerebral hemorrhage
2007-2012 TESPI****: Thrombolysis in elderly Stroke Patients in Italy: randomized controlled trial with i.v.t-PA vs standard treatment within 3 hrs of stroke in patients aged over 80 year (proponent of the study protocol)
2009-2011 DIAS 4*****: randomized controlled trial with i.v. desmoteplase within 3 to 9 hours after onset of an ischemic stroke
2008-2015 IRIS: randomized controlled trial of secondary prevention in patients with insulin resistance treated with pioglitazone
2010-2012 INTERACT2: randomized controlled trial with aggressive versus guideline blood pressure treatment in intracerebral hemorrhage
2010- STACI 2***: randomized controlled trial of early versus delayed carotid
endarterectomy in patients with ischemic stroke (in corso)
2012-2017 ECASS IV***: randomized controlled trial with i.v. t-PA between 4.5 and 9 hours of ischemic stroke onset
2015-2018 NAVIGATE-ESUS*;***: randomized controlled trial comparing rivaroxaban to aspirin in patients with embolic stroke of undetermined source (ESUS)
2015-2018 RE-SPECT-ESUS*;***: randomized controlled trial comparing dabigatran to aspirin in patients with embolic stroke of undetermined source (ESUS)
2015- SAFFO****: Silent Atrial Fibrillation aFter stroke, randomized controlled trial searching atrial fibrillation with implantable loop recorder or standard follow-up in patients with atherothrombotic or lacunar infarct (ongoing) (proponent of the study protocol)
2015- OPTION**: national register of patients with cryptogenic ischemic stroke and patent foramen ovale submitted or not submitted to percutaneous closure (ongoing) (proponent of the study protocol)
2015- ASTER****: national register of Prospective Risk of ICH after Acute Stroke Under Oral Anticoagulants (ongoing) (proponent of the study protocol)
2018-2019 RESTORE-BRAIN*: randomized controlled trial comparing GABA-A subunit antagonist to placebo to test functional recovery from ischemic stroke
2018-2020 THALES*: randomized controlled trial comparing ticagrelor+ASA vs ASA in early secondary prevention of ischemic stroke
2019- CHARM*: randomized controlled trial comparing glibenclamide to standard treatment in patients with malignant infarction
2019- ANNEXXA-I *: randomized controlled trial comparing andexanet to standard treatment in patients with brain hemorrhage while on therapy with anti-Xa drugs
2019- AXIOMATIC-I*: randomized controlled trial comparing dual antiplatelet therapy (ASA+clopidogrel) plus anti-IXa compound to dual antiplatelet therapy (ASA+clopidogrel)

* National Coordinator; ** Member of the Executive Committee; *** Member of the Steering Committee;**** Chairman; *****Member of the International Advisory Board

Premi internazionali
1994 Young investigator award, Stockholm 1994.
1995 Prize for excellence in stroke research , Bordeaux 1995
1996 First Sanofi prize for stroke research Cerebral embolism, Munich 1966
2021 The Spirit of Excellence Award for Commitment to excellence in stroke care. ESO/Angels

Roma 17 April 2023